Jun 12, 2023 / 06:20PM GMT
Salveen Jaswal Richter - Goldman Sachs Group, Inc., Research Division - VP
Great. Good morning, everyone. Thank you so much for joining us. I'm Salveen Richter, biotechnology analyst at Goldman Sachs, and we're really pleased to have Barry Greene, CEO of Sage with us here today. Thank you, Barry.
Barry E. Greene - Sage Therapeutics, Inc. - President, CEO & Director
Thank you. Great to be here. Thanks for having the sun come out, and thanks for Goldman for having us.
Salveen Jaswal Richter - Goldman Sachs Group, Inc., Research Division - VP
Did the sun come out?
Barry E. Greene - Sage Therapeutics, Inc. - President, CEO & Director
(inaudible)
Salveen Jaswal Richter - Goldman Sachs Group, Inc., Research Division - VP
Great.
Questions and Answers:
Salveen Jaswal Richter - Goldman Sachs Group, Inc., Research Division - VPGreat. So maybe to start here. Zuranolone is up for